Antiemetic Therapy

Aetna covers IV palonosetron, fosaprepitant, IV granisetron (including Sustol) and IV ondansetron for prevention of acute and delayed nausea/vomiting with initial and repeat courses of moderately and highly emetogenic chemotherapy (including high‑dose cisplatin), and permits palonosetron or fosaprepitant for treatment of CINV from low/minimally emetogenic regimens only when there is inadequate response or contraindication to FDA‑recommended ondansetron or granisetron; combination palonosetron+fosaprepitant is allowed for high‑emetic‑risk patients who have failed prior steroid plus 5‑HT3 therapy. Intravenous dolasetron for chemotherapy prevention, palonosetron/fosaprepitant for radiation‑induced nausea/vomiting, IV 5‑HT3s for motion sickness, aprepitant for gastroparesis, and aromatherapy for postoperative nausea/vomiting are considered experimental/investigational and not covered.

"Prevention of acute nausea or vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy, including high-dose cisplatin (palonosetron (Aloxi) or fos..."